Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer

Abstract Background Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. Plk1 is upregulated in many tumor types including colorectal cancer (CRC) and portends a poor prognosis. TAK-960 is an ATP-competitive Plk1 inhibitor that has...

Full description

Bibliographic Details
Main Authors: Peter J. Klauck, Stacey M. Bagby, Anna Capasso, Erica L. Bradshaw-Pierce, Heather M. Selby, Anna Spreafico, John J. Tentler, Aik Choon Tan, Jihye Kim, John J. Arcaroli, Alicia Purkey, Wells A. Messersmith, Keisuke Kuida, S. Gail Eckhardt, Todd M. Pitts
Format: Article
Language:English
Published: BMC 2018-02-01
Series:BMC Cancer
Subjects:
TAK-960
Plk1
Colorectal cancer
Patient-derived xenograft
Online Access:http://link.springer.com/article/10.1186/s12885-018-4036-z

Internet

http://link.springer.com/article/10.1186/s12885-018-4036-z

Similar Items